Synthesis of 3-Amino-4-(Hydroxymethyl)-β-Lactam Branch Point and Its Late-Stage C4 Functionalization with Ceftaroline-Sidechain Monobactams and Their Biological Evaluation

Abstract

Monocyclic β-lactams are an underexplored subclass of β-lactam antibiotics active against Gram-negative pathogens, but access to them requires long sequences reported across the patent and primary literature. We compare two alternative routes to 3-amino-4-(hydroxymethyl)-2-azetidinone, a synthon carrying handles at N1, C3 and C4, starting from ethyl glyoxylate and from (R)-glyceraldehyde acetonide. Both are assembled from published transformations; reported here are isolated yields for every step, including the conditions that failed, and execution of the β-lactam-forming sequence on a 50 g scale. Removal of the 2,4-dimethoxybenzyl group was strongly concentration-dependent, giving 94% on the glyoxylate-derived ester against 70% on the acetonide-derived alcohol, whereas the acetonide route replaces a low-yielding NaBH4 ester reduction (43 to 57%) with a near-quantitative oxidative cleavage/reduction sequence. Diverting one late-stage intermediate through copper-catalyzed azide–alkyne cycloaddition or direct thioether alkylation gave three sulfonated monobactams bearing a ceftaroline-derived C4 sidechain, in 0.10 to 0.29% overall yield over 15 steps. None reduced S. pneumoniae PBP1b activity below 50% at 100 μM, against an IC50 of 4.93 μM for aztreonam, and none inhibited wild-type E. coli or S. aureus at 128 μg/mL; weak inhibition was seen only in efflux-deficient and outer-membrane-permeabilized E. coli. C4 substitution through either linkage supports activity when the appended group also provides an uptake vector, which the ceftaroline-derived side chain does not, and it conferred no measurable target affinity either.